Core Viewpoint - China's service trade is expected to maintain steady growth in 2025, with a total import and export volume increasing by 7.4% year-on-year, and the structure of service trade continuously optimizing [1]. Group 1: Knowledge-Intensive Service Trade - Knowledge-intensive service trade is projected to grow, with imports and exports reaching 30,879.5 billion yuan, a year-on-year increase of 6.6% [1]. - The telecommunications, computer, and information services sectors are experiencing rapid growth in import and export rates [1]. - The surplus in knowledge-intensive services expanded by 1,581.7 billion yuan compared to the previous year [1]. Group 2: Technological Advancements - As China's enterprises enhance their R&D capabilities and technological levels, new competitive advantages are emerging in fields such as artificial intelligence, biomedicine, and high-end manufacturing [3]. - This advancement is driving the rapid growth of service exports related to intellectual property usage fees [3]. Group 3: Travel Service Trade - Travel service exports are maintaining high growth, with total imports and exports reaching 22,067 billion yuan in 2025, reflecting a year-on-year increase of 7.6% [6]. - Travel service exports have surged by 49.5% year-on-year, while imports have seen a modest increase of 1.4% [6].

Core Viewpoint - The rapid development of artificial intelligence and biomedicine is leading to unprecedented changes in the healthcare service industry [2][6]. IPO Details - Zhuozheng Medical Holdings Limited is set to be listed on the Hong Kong Stock Exchange on February 6, 2026, under the stock code "2677" [2]. - The company issued a total of 4,750,000 shares, raising a total of HKD 284 million, with a subscription rate of 2730.73 times for the public offering and 5.79 times for the international offering [2]. - Notable cornerstone investors include He Xiaopeng, CEO of Xiaopeng Motors, who subscribed for USD 1 million, and other tech companies with AI attributes [3]. Market Position and Growth - Zhuozheng Medical ranks first and second among private high-end comprehensive medical service institutions in terms of the number of cities covered and the number of paid patient visits in 2024 [9]. - The company has a strong reputation based on service quality, with high net promoter scores (NPS) of 81.1, 86.4, 85.9, and 87.6 from 2022 to 2025 [9]. Membership and Customer Retention - As of August 31, 2025, Zhuozheng Medical had 116,542 member accounts, with renewal rates increasing from 42% in 2022 to 67% in 2025 [11]. - The patient return rate also improved from 75.7% in 2022 to 82.7% in 2025, indicating strong customer loyalty [11]. Business Model - Zhuozheng Medical adopts a Costco-like model in the healthcare sector, focusing on a membership system and high-value services to drive growth [11][13]. - The company offers a range of services that cater to high-frequency health needs, allowing for longer customer retention periods and higher consumption frequency [13]. Financial Performance - Zhuozheng Medical achieved revenue growth from CNY 473 million in 2022 to CNY 959 million in 2024, with a compound annual growth rate (CAGR) of 42.2% [14]. - The gross profit also increased significantly, from CNY 44 million in 2022 to CNY 226 million in 2024, with a CAGR of 126.7% [14]. - The company turned profitable in 2024, with an adjusted net profit of approximately CNY 10.45 million in the first eight months of 2025 [14]. Investor Support - Zhuozheng Medical has received investments from notable firms such as Tencent, Matrix Partners, Tiantu Capital, and others, indicating strong institutional support [16][17]. - Investors believe that the company is well-positioned to meet the growing demand for high-quality healthcare services in China [17][18].

Core Viewpoint - The company expects a net profit of approximately -20 million yuan for the year 2025, which represents a reduction in losses of about 24.74 million yuan compared to the previous year, indicating a year-on-year loss reduction of approximately 55% [1] Group 1: Financial Performance - The company's net profit attributable to the parent company and the net profit after deducting non-recurring gains and losses are both expected to show losses for 2025 [1] - The overall sales revenue and gross margin have slightly decreased compared to the same period last year due to intense competition in the animal health industry and a decline in vaccine product prices [1] - The increase in accounts receivable due to delayed customer payments has led to a rise in credit impairment losses [1] - The depreciation of fixed assets has increased following the commissioning of a new vaccine workshop [1] Group 2: Strategic Developments - The company is actively expanding into new areas of biopharmaceutical technology and optimizing its marketing layout, resulting in increased product sales volume [1] - The company has made significant progress in the research and development of multi-valent vaccines, with new products such as the swine fever genetic engineering subunit vaccine and the swine streptococcus disease/infectious pleuropneumonia bivalent vaccine being launched [1] - The total period expenses have significantly decreased compared to the previous year, contributing to a reduction in net profit losses by approximately 55% [1] Group 3: Investment and Future Plans - The company has invested in a stake in the innovative drug company Yangzhou Shizhi Yuan Biotechnology Co., Ltd., which is conducting clinical research on innovative drugs [2] - The company plans to acquire a controlling stake in Shizhi Yuan to synergize its human and animal health businesses, leveraging its advanced biotechnology and production advantages in the human innovative drug sector [2] - The company aims to expedite the research and development and market launch of several innovative drugs, including monoclonal antibodies for AIDS [2]

第四个消息，近期国常会强调将出台进一步促进民间投资发展的若干措施，拓展民间投资空间，重点支 持民间资本加大对新质生产力、新兴服务业、新型基础设施等领域的投资。此外，国常会还强调将加快 生物医药技术的研发和成果转化应用。这些方案有助于形成短期向上推动预期，因此也算利好。 最后一个消息，昨日监管部门严肃查处了东方通的严重财务造假案。此前已对此进行过解读，此处不再 赘述。只希望民间赔偿机制能尽快建立，将投资者损失降到最低。无论如何，这一消息有助于推动市场 公平公正，对市场中长期向好构成利好。 9月14日，和讯投顾高璐明称，对周末重磅消息进行解读，看看这两天国内外市场发生了哪些重要大 事，以及这些大事将如何影响下周市场走势。 第一个消息，今日中、美将在西班牙进行关税和贸易会谈，主要讨论美方单边关税措施及"301调查"等 相关问题。这标志着贸易谈判再次开启，从今日起需密切关注会谈结果，因其将影响短期市场走势。若 会谈顺利，将对下周市场形成积极促进作用；若会谈不顺，则可能引发市场短期震荡和波动，因此需持 续关注。 第二个消息，昨晚美方再次出手，将国内多家实体列入管制出口黑名单。随后，商务部决定对原产于美 方的相关模拟芯片 ...